Day 1 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Author(s):

Kaitlyn Bader, Assistant Managing Editor

Key Takeaways

Arcutis Biotherapeutics will present promising long-term data on roflumilast for young children with atopic dermatitis, emphasizing its safety and efficacy.
The conference will highlight the clinical integration of newly approved biologics nemolizumab and lebrikizumab in atopic dermatitis treatment.
The SCALE UP study will demonstrate upadacitinib's effectiveness in providing symptom relief across various skin types and racial groups.
The psychosocial impact of atopic dermatitis, including effects on mental health and quality of life, will be a significant focus at the conference.

Catch up on coverage from the first day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Previewing the 2025 Revolutionizing Atopic Dermatitis Conference

Catch up on what to expect at this year's RAD conference in Nashville, Tennessee.

Road to RAD: Dermatology Times Board Member Presenters

Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025

Arcutis Biotherapeutics showcases promising long-term results of roflumilast for atopic dermatitis in young children at RAD 2025, emphasizing safety and efficacy.

Road to RAD: What to Expect

Co-chairs Jonathan Silverberg, MD, PhD, MPH, and Raj Chovatiya, MD, PhD, MSCI, gave insight into what attendees can look forward to at this year's meeting.

SCALE UP Demonstrates AD Symptom Relief Across All Skin Types With Upadacitinib

A poster at RAD 2025 detailed the patient-reported outcomes across skin types and racial groups.

Spotlighting Biologic Advancements and Novel Pathways in Atopic Dermatitis

At RAD 2025, Jonathan Silverberg, MD, PhD, MPH, provided an in-depth look at the clinical integration of newly approved biologics nemolizumab and lebrikizumab in AD.

INTEGUMENT-INFANT Phase 2 Trial Will Assess Roflumilast in Pediatric Patients with AD

Discover groundbreaking insights from the RAD 2025 conference on roflumilast's potential to transform treatment for infant atopic dermatitis.

The Psychosocial Toll of Atopic Dermatitis Across All Ages

At RAD 2025, Mona Shahriari, MD, emphasized the cumulative life course impairment of AD in pediatric and adult patients, highlighting its impact on sleep, mental health, family well-being, and quality of life.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!